Search results
Crinecerfont Promising for Congenital Adrenal Hyperplasia
Medscape· 6 days agoCrinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor...
Fine Particulate Matter Raises Type 2 Diabetes Risk in Women
Medscape· 2 days agoLong-term exposure to fine particulate matter increased type 2 diabetes in women of childbearing...
Counting Steps or Watching the Clock for a Longer Life?
Medscape· 5 days agoFor example, the World Health Organization advises at least 150 minutes of moderate physical...
Could 'Medical Editor' Be Your Next Career Move?
Medscape· 5 days agoThis free training program could be the stepping stone you need to pursue a career in medical journalism.
Age, Race, Insurance Impact Initial Sarcoidosis Severity
Medscape· 3 days agoLack of insurance was significantly associated with more severe lung disease at initial...
U.S. Credit: We’re Not in Uncharted Territory
ETF Trends· 5 days agoWhile the money and bond markets continue their Fed-watch saga, there is one constant that we have been emphasizing for the fixed income landscape: a new...
Trump vs. Biden Polls: Conviction Not Having Big Impact Yet
New York Magazine· 2 days agoYou can be forgiven if you thought the criminal conviction of Donald Trump on 34 felony counts by a...
Focusing on Reward a Solution to MS-Related Fatigue?
Medscape· 3 days agoInterventions that stimulate the reward system may be the most effective treatment for fatigue directly related to multiple sclerosis (MS), experts said....
Investor home purchases jump for the first time in two years. Here's what that means for buyers
CNBC· 3 days agoIn this context, investors are defined as any institution or business that purchases residential...
'Outstanding' 5 Year PFS With Lorlatinib in ALK+ NSCLC
Medscape· 7 days agoFive-year follow-up data from the landmark CROWN trial shows significant progression-free survival in ALK+ NCSLC, but some experts question the use of crizotinib as the comparator drug.